Latest News
Aspen Neuroscience completes Cohort 3 and 4 dosing in Parkinson's disease trial
1 July 2026 - Aspen Neuroscience Inc, a clinical-stage regenerative medicine biotechnology company developing personalised, autologous cell therapies, announced on Tuesday the completion of dosing in Cohort 3 and Cohort 4 of its ongoing Phase 1/2a AS...
Will Therapeutics announces CQDM-backed research collaboration to improve treatment for anorexia nervosa and other compulsive disorders
1 July 2026 - Will Therapeutics, a Canada-based early-stage biotechnology company developing novel small-molecule medicines for psychiatric and compulsive disorders, announced on Tuesday that its collaborative research project with the Douglas Hospit...
Biohaven completes enrolment in opakalim RISE 3 epilepsy study
1 July 2026 - Clinical-stage biopharmaceutical company Biohaven Ltd (NYSE:BHVN) announced on Tuesday the completion of enrolment in RISE3, a pivotal Phase 2/3 randomised, double-blind, placebo-controlled study evaluating its selective Kv7.2/7.3 chann...
ADC Therapeutics completes enrolment in Phase 1b ZYNLONTA combination trial
1 July 2026 - ADC Therapeutics SA (NYSE: ADCT), a Swiss developer of antibody drug conjugates (ADCs), announced on Tuesday the completion of enrolment in the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA (l...
Sanofi reports positive phase 3 results for Nexviazyme in infantile-onset Pompe disease
30 June 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Tuesday that its Phase 3 Baby-COMET study met its primary endpoint, with treatment-naïve infants aged six months and younger with infantile-onset...